This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
New research has uncovered a surprising culprit underlying cardiovasculardiseases in obesity and diabetes -- not the presence of certain fats, but their suppression. Ironically, the findings could ultimately lead to therapies that maintain high levels of these protective lipids in patients with obesity.
Driven by an older, more diverse population, along with a significant increase in risk factors including high blood pressure and obesity, total costs related to cardiovasculardisease (CVD) conditions are likely to triple by 2050, according to recent projections. At least 6 in 10 U.S.
Men with cardiovasculardisease risk factors, including obesity, face brain health decline a decade earlier—from their mid 50s to mid 70s—than similarly affected women who are most susceptible from their mid 60s to mid 70s, suggest the findings of a long term study, published online in the Journal of Neurology Neurosurgery & Psychiatry.
BackgroundObesity is a global epidemic and a major risk factor for cardiovasculardiseases. This study aims to investigate the impact of weight loss after LSG on the left ventricular myocardial work (LVMW) in obese patients and explore the clinical value of the left ventricular pressure - strain loop (LV - PSL).MethodsThirty
ET Tuesday, June 4, 2024 DALLAS, June 4, 2024 — Driven by an older, more diverse population, along with a significant increase in risk factors including high blood pressure and obesity, total costs related to.
Background Heart failure (HF) is a serious and common condition affecting millions of people worldwide, with obesity being a major cause of metabolic disorders such as diabetes and cardiovasculardisease. During the 4.22-year
This new insight into the flow of fats through the body points to new therapeutic targets for mitigating diseases like ASCVD, non-alcoholic fatty liver disease, obesity, diabetes, peripheral neuropathy, and neurodegeneration.
Babies born to pregnant women with obesity are more likely to develop heart problems and diabetes as adults due to fetal damage caused by the high-fat, high-energy diet of their mother.
New research from Weill Cornell Medicine has uncovered a surprising culprit underlying cardiovasculardiseases in obesity and diabetesnot the presence of certain fats, but their suppression. The study, published Feb.
Cardiovasculardisease represents a significant risk factor for mortality in individuals with type 2 diabetes mellitus (T2DM). High-density lipoprotein (HDL) is believed to play a crucial role in maintaining c.
Cardiovasculardisease (CVD) is closely associated with the triglyceride glucose (TyG) index and its related indicators, particularly its combination with obesity indices. However, there is limited research on.
In today’s society, the prevalence of obesity has become a significant concern. have obesity, and this rate has increased by more than 10 percentage points in the past two decades. Understanding the prevalence of obesity is crucial in comprehending why events like Healthy Weight Week are essential. of adults in the U.S.
With Medicare now covering semaglutide for people with obesity and cardiovasculardisease who don't have diabetes, a study looks at who that might include, depending on what cutoffs prescription plans apply.
The following are key points to remember from a European Society of Cardiology (ESC) clinical consensus statement on obesity and cardiovasculardisease (CVD).
Despite its known correlations with risk of cardiovasculardisease, awareness and testing for Lipoprotein (a) lags that of other serological markers with estimates that less than 1% of the US population have undergone screening.
Obesity is a recognized public health epidemic with a prevalence that continues to increase dramatically in nearly all populations, impeding progress in reducing incidence rates of cardiovasculardisease. Circulation, Ahead of Print.
The five classic risk factors for cardiovasculardisease are well knownsmoking, high blood pressure, high cholesterol, diabetes, and underweight or overweight/obesity. All increase the likelihood of heart ailments down the road.
Driven by common pathophysiologic underpinnings (eg, inflammation and neurohormonal dysregulation), cardiovasculardisease, cognitive impairment, and frailty also share the following risk factors: hypertension, diabetes, obesity, sedentary behavior, and tobacco use.
Atherosclerosis (ASVD) remains a leading driver of cardiovasculardisease (CVD), a global health challenge that claims millions of lives each year. School-Based Interventions: Creating Healthy Habits Early Programs that limit sugar-sweetened beverages and increase physical education very likely reduce childhood obesity.
Obesity is a multifaceted disease that is directly and indirectly implicated in atherosclerotic cardiovasculardisease (CVD), heart failure (HF), atrial fibrillation (AF), and multiple CVD risk factors, including dyslipidemia, hypertension, type 2 diabetes mellitus (DM), and sleep disorders.
(MedPage Today) -- Men at high risk of cardiovasculardisease had brain volume changes a decade earlier than women, U.K. Cardiovascular risk and obesity had the strongest relationship with lower gray matter volume in men between. Biobank data showed.
A projected rise in heart disease and stroke – along with several key risk factors, including high blood pressure and obesity – is likely to triple related costs to $1.8 population could be affected by cardiovasculardisease within the next 30 years, according to two new science reports. and Susan F. to 61% of the U.S.
We projected through 2050, overall and by age and race and ethnicity, accounting for changes in disease prevalence and demographics.RESULTS:We estimate that among adults, prevalence of hypertension will increase from 51.2% to 26.8%) and obesity (43.1% Prevalences of coronary disease (7.8% in 2020 to 61.0% Diabetes (16.3%
Overweight and obesity have reached epidemic proportions, affecting more than 70% of the U.S. 1 In addition to numerous health consequences, obesity contributes to cardiovasculardisease indirectly through the development of risk factors and directly through various biologic mechanisms.2
Overweight and obesity are common in patients with heterozygous familial hypercholesterolemia (HeFH) and are associated with a greater risk of atherosclerotic cardiovasculardisease (ASCVD) starting in childhood and regardless of LDL-C level and lipid-lowering medication, according to a cross-sectional analysis published Jan.
Semaglutide reduces cardiovascular events, regardless of baseline glycated hemoglobin (HbA1c), among people with overweight or obesity and established atherosclerotic cardiovasculardisease, according to a study published online June 22 in Diabetes Care.
Obesity, a major risk factor for cardiovasculardisease (CVD), is associated with hypertension and vascular dysfunction. Perivascular adipose tissue (PVAT), a metabolically active tissue surrounding blood vess.
years; p < 0.001), had more cardiovascular risk factors, target organ damage and cardiovasculardisease (CVD) in comparison with those without hypertension. These patients were older (65.8 ± 10.9 vs. 51.6 ± 14.7 Conclusions About half of patients attended in primary care settings have hypertension in Spain.
The triglyceride-glucose (TyG) index and its combination with obesity indicators can predict cardiovasculardiseases (CVD). However, there is limited research on the relationship between changes in the triglyc.
Triglyceride and glucose (TyG) index, a surrogate marker of insulin resistance, has been validated as a predictor of cardiovasculardisease. However, effects of TyG-related indices combined with obesity marker.
Among hypertensive cohorts across different nations, the relationship between the triglyceride-glucose index (TyG) and its conjunction with obesity metrics in relation to cardiovasculardisease (CVD) incidence.
A new JAMA study revealed that a shocking 90% of US adults are at risk of developing cardiovascular-kidney-metabolic (CKM) syndrome, underscoring the need for preventative action before we face a wave of CKM-related heart disease. Stage 4 (heart disease, with or without kidney disease) – 9.2% in Whites).
Metabolic syndrome, today affecting more than 20% of the US population, is a group of 5 conditions that often coexist and that strongly predispose to cardiovasculardisease. How these conditions are linked mechanistically remains unclear, especially two of these: obesity and elevated blood pressure.
Non-alcoholic fatty liver disease (NAFLD), now known as metabolic-associated steatotic liver disease (MASLD), is the most common liver disease worldwide, with a prevalence of 38%. In these patients, cardiovasculardisease (CVD) is the number one cause of mortality rather than liver disease.
Multivariable logistic models evaluated associations of RARs with prevalent CVD, hypertension, obesity, and central adiposity. Participants (mean age, 49 years) in the highest versus lowest tertile of relative amplitude (greater circadian rhythmicity) had 39% to 62% lower odds of prevalent CVD, hypertension, obesity, and central adiposity.
When it comes to cardiovasculardisease, two of the biggest risk factors we must consider are: ApoB concentration - A measure of the number of circulating lipid particles. Trends in the number of obese and severely obese people by region. Rates of obesity have tripled in the last 60 years. But only moderately.
Pre-eclampsia and heart failure have common risk factors, including hypertension, obesity and diabetes. Multiple logistic regression analysis was used to evaluate the impact of heart failure on the risk of pre-eclampsia, with adjustment for established risk factors and other cardiovasculardiseases.
Cardiovasculardisease (CVD) is a critical public health concern, with risk factors such as high blood pressure, abnormal blood sugar levels, elevated cholesterol, and obesity beginning in childhood.
Obesity is a global pandemic and is a recognised risk factor for cardiovasculardiseases. Therefore, we conducted an observational study with a cohort of 196 participants, comparing various echocardiographic parameters in normal weight individuals and those who were overweight or obese but had no other risk factors.
24 theme of Cardiovascular Care for All, we will highlight our commitment to underserved populations and present subset analyses in women and Hispanic/Latinx patients as well as in patients with obesity." "Complementing the ACC.24
Cardiovasculardiseases (CVD) are the leading cause of mortality and morbidity worldwide. The study reveals a link between Zn, Cu, and the Zn/Cu ratio and cardiovasculardisease risk. A higher Zn/Cu ratio may protect against CVD, while elevated Cu levels are linked to obesity, fibrinogen levels, and HbA1C.
In a trial in patients with cardiovasculardisease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8
Publication date: Available online 5 October 2024 Source: The American Journal of Cardiology Author(s): Ishaque Hameed, Khushboo Nusrat, Adeena Jamil, Kaneez Fatima, Abdul Mannan Khan Minhas, Stephen J. Greene, Andrew J Sauer, Javed Butler, Muhammad Shahzeb Khan
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content